Company Synairgen plc

Equities

SNG

GB00B0381Z20

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:20 2024-04-26 am EDT			5-day change	1st Jan Change
6.49 ^GBX	-1.52%		-3.85%	+8.62%

2023	FTSE 100 Finishes Slightly Lower After Steady Session	DJ
2023	Synairgen names Phytome's Joseph Colliver as CFO	AN

Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company; Synairgen Inc. and Synairgen Research (Ireland) Limited. The Company is developing SNG001, an investigative formulation of inhaled interferon beta (IFN-B), for the treatment and prevention of various viral lung infections in high-risk patient groups. The Company has developed and is testing an inhaled formulation of IFN-B designed to directly target the lungs, the primary site of many viral lung infections, including COVID-19.

Number of employees: 34

Managers	Title	Age	Since
Richard Marsden CEO	Chief Executive Officer	57	03-10-31
Joseph Colliver DFI	Director of Finance/CFO	43	Nov. 05
Marcin Mankowski CTO	Chief Tech/Sci/R&D Officer	-	23-10-02
Jody Brooks CTO	Chief Tech/Sci/R&D Officer	-	04-01-31
Phillip Monk CTO	Chief Tech/Sci/R&D Officer	55	06-09-30
Richard Hennings PRN	Corporate Officer/Principal	-	21-02-28
Helen Gearing PRN	Corporate Officer/Principal	-	21-11-30
Gareth Walters LAW	General Counsel	-	21-10-12
Richard Francis PRN	Corporate Officer/Principal	-	21-08-31
Simon Holden SEC	Corporate Secretary	48	-

Members of the board	Title	Age	Since
Simon Shaw CHM	Chairman	59	03-05-31
Stephen Holgate FOU	Founder	77	03-05-31
Richard Marsden CEO	Chief Executive Officer	57	03-10-31
David Campbell BRD	Director/Board Member	80	06-04-10
Felicity Gabbay BRD	Director/Board Member	72	22-09-28
Phillip Monk CTO	Chief Tech/Sci/R&D Officer	55	06-09-30
Amanda Radford BRD	Director/Board Member	53	22-11-30
Joseph Colliver DFI	Director of Finance/CFO	43	Nov. 05

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	201,374,975	195,153,037 ( 96.91 %)	0	96.91 %

Name	Equities	%	Valuation
TFG Asset Management UK LLP 28.15 %	56,696,000	28.15 %	4 M p
Woodford Investment Management Ltd. 10.60 %	21,341,293	10.60 %	1 M p
Simon Shaw 0.7604 %	1,531,239	0.7604 %	98 551 p
Richard Marsden 0.4945 %	995,771	0.4945 %	64 088 p
Stephen Holgate 0.4528 %	911,876	0.4528 %	58 688 p
John Ward 0.3645 %	734,092	0.3645 %	47 246 p
ISPartners Investment Solutions AG 0.2935 %	591,000	0.2935 %	38 037 p
Phillip Monk 0.2105 %	423,934	0.2105 %	27 284 p
Octopus Investments Ltd. 0.2057 %	414,310	0.2057 %	26 665 p
David Campbell 0.1646 %	331,554	0.1646 %	21 339 p

Synairgen Plc

Mailpoint 810 Southampton General Hospital

SO16 6YD, Southampton

+44 23 8051 2800

http://www.synairgen.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.0649 GBP

Average target price

0.4 GBP

Spread / Average Target

+516.33%

Consensus

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
SYNAIRGEN PLC	+8.62%	16.28M
IQVIA HOLDINGS INC.	+1.51%	42.75B
MODERNA, INC.	+8.57%	41.34B
LONZA GROUP AG	+49.22%	41.61B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research